ASCO: Guardant blood test guides breast cancer therapy switches, extending survival in AZ-backed study
A new study sponsored by AstraZeneca suggests that using the Guardant360 CDx test to spot early signs of therapy resistance in advanced breast cancer patients and inform a treatment change could slash the risk of disease progression or death by half.
A new study sponsored by AstraZeneca suggests that using the Guardant360 CDx test to spot early signs of therapy resistance in advanced breast cancer patients and inform a treatment change could slash the risk of disease progression or death by half.
